---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004802"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:15:58.210570+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoDyn restructures $43.8M Samsung debt; payment contingent on revenue

## Summary
- Total balance of $43,821,231.32 restructured; only $250,000 due by Dec 31, 2024; remainder contingent on 20% of qualifying annual revenue.
- Interest will not accrue on the balance during repayment period; debt is repayable only upon achieving defined 'Revenue' events.
- Letter Agreement terminates Master Services Agreement from April 2019; Samsung will ship specified drug product to storage at CytoDyn’s discretion.
- CytoDyn states it has sufficient drug product and substance for planned clinical activity; will transition manufacturing services to other current providers.

## SEC filing metadata
- accession: 0001558370-24-004802
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/0001558370-24-004802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/cydy-20240403x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004802
- JSON: https://secwatch.observer/filing/0001558370-24-004802.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004802.txt

## Key facts
- Material Agreements
  CytoDyn Inc. terminated Letter Agreement with Samsung BioLogics Co., Ltd. valued at $43,821,231.32 total balance, $250,000 due by Dec 31, 2024, remainder contingent on Revenue event (effective 2024-04-03).
  - Action: termination
  - Counterparty: Samsung BioLogics Co., Ltd.
  - Value: $43,821,231.32 total balance, $250,000 due by Dec 31, 2024, remainder contingent on Revenue event
  - Effective: 2024-04-03
  source text: On April 3, 2024, CytoDyn Inc. (the “Company”) and Samsung BioLogics Co., Ltd. (“Samsung”) executed an agreement (the “Letter Agreement”), wherein the parties reached agreement for an orderly process for winding down services and a restructuring of the amount payable by the Company to Samsung (the “Total Balance”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837024004802/0001558370-24-004802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.